Nevirapine
Thông số
129618-40-2Số CAS
603-345-0Số EC
2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-oneTên IUPAC
C15H14N4OCông thức hóa học
266.3 g/molKhối lượng phân tử
nevirapine; 129618-40-2; Viramune; BI-RG-587; Nevirapine anhydrous; Viramune XR; BIRG 0587; Nevirapine, anhydrous; Nevirapine teva; BIRG587; BIRG-0587; 11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one; Nevirapina; 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE; DTXSID7031797; 99DK7FVK1H; Nevirapinum anhydrous; NSC-641530; BIRG0587; CHEBI:63613; NSC641530; 6H-Dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-; DTXCID9010787; 2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo[9.4.0.03,8]pentadeca-1(11),3,5,7,12,14-hexaen-10-one; BI RG 587; nevirapinum; 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo(9.4.0.0^(3,8))pentadeca-1(15),3,5,7,11,13-hexaen-10-one; 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,11,13-hexaen-10-one; 2-cyclopropyl-7-methyl-2,4,9,15-tetrazatricyclo(9.4.0.03,8)pentadeca-1(11),3,5,7,12,14-hexaen-10-one; 6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE, 11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-; Hemihydrate, Nevirapine; RefChem:853798; J05AG01; NEVIRAPINE TABLETS FOR ORAL SUSPENSION; 603-345-0; 4-amino-1-((2R,4R)-2-(hydroxymethyl)-1,3-oxathiolan-4-yl)pyrimidin-2-one; NVP; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one; MFCD00866928; BIRG-587; CHEMBL57; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one; 11-CYCLOPROPYL-4-METHYL-5H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6(11H)-ONE; NEV; MLS000084585; NCGC00065890-02; SMR000048458; S1742; 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,12,14-hexaen-10-one; BI-RG 587; Viramune(TM); Viramune (TN); CAS-129618-40-2; HSDB 7164; Nevirapine & CD4-IgG; Nevirapine & PRO 140; UNII-99DK7FVK1H; NSC 641530; Nevirapine (JAN/USP/INN); Nevirapine); 11-cyclopropyl-4-methyl-5H-dipyrido[[?],[?]][1,4]diazepin-6-one; BIRG 587; Nevirapine RS; NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE; Viramune IR; 1vrt; 2hny; Nevirapine [USAN:USP:INN:BAN]; BI-RG-587 & CD4-IgG; Nevirapine (Standard); Nevirapine (Viramune); NEVIRAPINE [MI]; Opera_ID_934; NEVIRAPINE [INN]; NEVIRAPINE [JAN]; NEVIRAPINE [HSDB]; NEVIRAPINE [USAN]; NEVIRAPINE [VANDF]; Epitope ID:231711; Nevirapine (anhydrous) CRS; NEVIRAPINE [MART.]; SCHEMBL3318; NEVIRAPINE [WHO-DD]; MLS000759409; MLS001055309; MLS001201730; MLS001424058; MLS006011423; BIDD:GT0326; NEVIRAPINE [EMA EPAR]; BDBM1434; orb1308075; orb3141273; NEVIRAPINE [ORANGE BOOK]; SCHEMBL29393780; SCHEMBL29614675; SCHEMBL30267890; GTPL12676; NEVIRAPINE [EP MONOGRAPH]; NEVIRAPINE [USP IMPURITY]; HMS2051J09; HMS2231O23; HMS3264D21; HMS3371E03; HMS3393J09; HMS3655I08; HMS3715B10; HMS5079D22; NEVIRAPINE [USP MONOGRAPH]; Pharmakon1600-01503842; ALBB-027264; BSB41895; MSK10168; Tox21 110982; Tox21_110982; Tox21_200770; AC-643; AC1280; BBL010768; EBC-11254; HY-10570R; NSC759902; STK580320; NEVIRAPINE ANHYDROUS [USP-RS]; NEVIRAPINE ANHYDROUS [WHO-IP]; AKOS005504351; Nevirapine for peak identification CRS; Tox21_110982_1; AB07544; CCG-100939; DB00238; KS-5019; NC00189; NN15304; NSC-759902; NCGC00065890-03; NCGC00065890-04; NCGC00065890-05; NCGC00065890-07; NCGC00065890-14; NCGC00258324-01; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody); HY-10570; N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin; Nevirapine 100 microg/mL in Acetonitrile; SY009679; BI-RG 587;NSC 641530;NVP; DB-041930; N0922; NEVIRAPINUM ANHYDROUS [WHO-IP LATIN]; NS00004959; SW197569-2; C07263; D00435; EN300-119500; AB00393001-13; AB00393001-15; AB00393001_16; AB00393001_17; F358078; Q263713; BRD-K15502390-001-19-1; BRD-K15502390-001-20-9; F2173-0607; Z1521553473; Nevirapine (anhydrous), European Pharmacopoeia (EP) Reference Standard; Nevirapine anhydrous, United States Pharmacopeia (USP) Reference Standard; Nevirapine, Pharmaceutical Secondary Standard; Certified Reference Material; 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido-[3,2-b:2',3'-e][1,4]diazepin-6-one; 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b :2',3'-e][1,4 ]diazepin-6-one; 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2 ,3 -e][1,4]diazepin-6-one; 6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-; Nevirapine for peak identification, European Pharmacopoeia (EP) Reference Standard; 11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2 inverted exclamation mark ,3 inverted exclamation mark -e][1,4]diazepin-6-one; 2-cyclopropyl-7-methyl-2,4,9,15-tetraazatricyclo[9.4.0.0,3,8]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one; Nevirapina, anhidraTên gọi khác
Sản phẩm chứa Nevirapine
ビラミューン錠200NEVIRAPINA TEVA 400 MG COMPRIMIDOS DE LIBERACION PROLONGADA EFGNEVIRAPINA TARBIS FARMA 400 MG COMPRIMIDOS DE LIBERACION PROLONGADA EFGNEVIRAPINA KERN PHARMA 200 mg COMPRIMIDOS EFGNEVIRAPINA AUROVITAS 400 MG COMPRIMIDOS DE LIBERACION PROLONGADA EFGVIRAMUNE 50 mg/5 ml SUSPENSION ORALVIRAMUNE 400 mg COMPRIMIDOS DE LIBERACION PROLONGADAVIRAMUNE 200 mg COMPRIMIDOSVIRAMUNE 200 mg COMPRIMIDOSNEVIRAPINA NORMON 200 MG COMPRIMIDOS EFGVIRAMUNE 400 mg, comprimé à libération prolongéeVIRAMUNE 200 mg, comprimé
Trang 1/6
Công ty đang bán Nevirapine
CT
Công ty TNHH BRV HealthcareViet NamTrang 1/4